NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 27th May 2009 Thiazide diuretics are unsurpassed as initial therapy for reduction of cardiovascular (including stroke) and renal risk, a review of ALLHAT has concluded. ALLHAT, still the largest […]
Category Archives: Cardiovascular disease
NPC Archive Item: WATCHing and wondering: no clear answers about antithrombotics in heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 27th May 2009 The WATCH study compared adjusted dose warfarin, aspirin and clopidogrel in patients with heart failure. The study was underpowered but does not provide strong evidence that […]
NPC Archive Item: NICE publishes guidance on rivaroxaban▼ for prevention of VTE after hip and knee surgery
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 5th May 2009 NICE technology appraisal guidance 170▼ recommends oral rivaroxaban (Xarelto®) as an option for the prevention of venous thromboembolism (VTE) in adults having elective total hip replacement surgery or […]
NPC Archive Item: Is clopidogrel ACTIVE for atrial fibrillation?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 17th April 2009 Clopidogrel plus aspirin reduced the risk of a vascular composite end point compared with aspirin alone in people with AF who were at increased risk of […]
NPC Archive Item: Resources relating to Better Care, Better Value indicators
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 9th April 2009 The NHS Institute for Innovation and Improvement has recently released four Better Care, Better Value Indicators (BCBV) relating to prescribing. NPC includes resources which will help […]
NPC Archive Item: The polypill – interesting DOO data, but no POOs yet
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6th April 2009 The Indian Polycap Study (TIPS), a short term, phase II study, suggests that a combination capsule which includes five active ingredients has similar effects on cardiovascular […]
NPC Archive Item: Rosuvastatin produces a small absolute reduction in venous thromboembolism (VTE) in people at low baseline risk
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6th April 2009 In this analysis of the previously reported JUPITER study, rosuvastatin 20mg daily compared with placebo reduced the risk of symptomatic VTE in people with few elevated […]
NPC Archive Item: Rosuvastatin has no CV benefits in patients undergoing haemodialysis
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6th April 2009 The AURORA study found rosuvastatin had no cardiovascular mortality or morbidity benefits in patients with end-stage renal disease undergoing haemodialysis. Action Patients with chronic kidney disease […]
NPC Archive Item: Prasugrel▼ (Efient®) in patients with STEMI
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25th March 2009 A pre-specified subgroup analysis of the TRITON-TIMI 38 trial suggests that prasugrel ▼ may be more effective than clopidogrel in those with STEMI ACS undergoing PCI. Major […]
NPC Archive Item: Dronedarone in atrial fibrillation – does ATHENA provide the answers?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 5th March 2009 In the ATHENA trial of 4,628 patients with atrial fibrillation (AF) or flutter, dronedarone was more effective than placebo in reducing cardiovascular (CV) hospital admissions or […]